Ophthalmic Applicator Displacement As a Method of Treating Large Diffuse Uveal Melanomas

Overview

Journal J Contemp Brachytherapy

Date 2023 Jul 10

PMID 37425204

Authors

Anna Markiewicz

Konrad Skorkiewicz

Agata Bogdal

Dominik Medon

Mirella Swider

Elz Bieta Korab-Chrzanowska

Joanna Kowal

Magdalena Debicka-Kumela

Bozena Romanowska-Dixon

Affiliations

Soon will be listed here.

Abstract

Purpose: The presentation of results of an ophthalmic plaque displacement as a brachytherapy treatment method of large diffuse uveal melanomas.

Material And Methods: This was a retrospective analysis of treatment results of 9 patients with large diffuse uveal melanomas using ophthalmic plaque displacement. Patients were treated with this method in our center between 2012 and 2021 (last follow-up visit in 2023). To achieve appropriate radiation dose distribution for large tumors with a base greater than 18 mm, brachytherapy (Ru in 7 patients and I in 2 patients) with applicator displacement was used as primary treatment. Median follow-up was 2.9 years, and for patients with positive primary treatment results, it was 1.7 months. Median time to local relapse was 2.3 years.

Results: In 5 patients, a positive result of local treatment was obtained, out of whom, one patient underwent enucleation due to complications. In the next 4 cases, local recurrence developed. In all tumors, the use of applicator displacement method caused that planning target volume (PTV) was effectively covered with treatment isodose.

Conclusions: Brachytherapy with ocular applicator displacement allows for the treatment of tumors with base measurements larger than 18 mm. The application of this method may be considered as an alternative for eye enucleation in particular cases of large diffuse tumors, such as a neoplasm of the eye with vison, or when a patient does not consent to enucleation.

Citing Articles

A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachytherapy in uveal melanoma.

Miguel D, de Frutos J, Alonso P, Garcia-Alvarez C, Saornil M, Diezhandino P J Contemp Brachytherapy. 2023; 15(5):350-356.

PMID: 38026075 PMC: 10669921. DOI: 10.5114/jcb.2023.132658.

References

Kowal J, Markiewicz A, Debicka-Kumela M, Bogdali A, Jakubowska B, Karska-Basta I . Analysis of local recurrence causes in uveal melanoma patients treated with I brachytherapy - a single institution study. J Contemp Brachytherapy. 2020; 11(6):554-562. PMC: 6964341. DOI: 10.5114/jcb.2019.90985. View

Sas-Korczynska B, Markiewicz A, Romanowska-Dixon B, Pluta E . Preliminary results of proton radiotherapy for choroidal melanoma - the Kraków experience. Contemp Oncol (Pozn). 2014; 18(5):359-66. PMC: 4248051. DOI: 10.5114/wo.2014.42233. View

Shields J, Shields C . Management of posterior uveal melanoma: past, present, and future: the 2014 Charles L. Schepens lecture. Ophthalmology. 2014; 122(2):414-28. DOI: 10.1016/j.ophtha.2014.08.046. View

Mirshahi R, Sedaghat A, Jaberi R, Azma Z, Mazloumi M, Naseripour M . Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results. BMC Ophthalmol. 2022; 22(1):309. PMC: 9288719. DOI: 10.1186/s12886-022-02521-9. View

. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2013; 13(1):1-14. DOI: 10.1016/j.brachy.2013.11.008. View

Muller K, Nowak P, de Pan C, Marijnissen J, Paridaens D, Levendag P . Effectiveness of fractionated stereotactic radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys. 2005; 63(1):116-22. DOI: 10.1016/j.ijrobp.2005.01.058. View

Sanchez-Tabernero S, Garcia-Alvarez C, Munoz-Moreno M, Diezhandino P, Alonso-Martinez P, de Frutos-Baraja J . Pattern of Local Recurrence After I-125 Episcleral Brachytherapy for Uveal Melanoma in a Spanish Referral Ocular Oncology Unit. Am J Ophthalmol. 2017; 180:39-45. DOI: 10.1016/j.ajo.2017.05.019. View

. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12):1684-93. DOI: 10.1001/archopht.124.12.1684. View

Modorati G, Miserocchi E, Galli L, Picozzi P, Rama P . Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol. 2008; 93(1):40-4. DOI: 10.1136/bjo.2008.142208. View

10.

Char D, Kroll S, Castro J . Ten-year follow-up of helium ion therapy for uveal melanoma. Am J Ophthalmol. 1998; 125(1):81-9. DOI: 10.1016/s0002-9394(99)80238-4. View

11.

Markiewicz A, Gerba-Gorecka K, Jakubowska B, De Bicka-Kumela M, Kowal J, Karska-Basta I . Brachytherapy or enucleation in ring melanoma patients: which is better? Preliminary results of the authors' own experiences. J Contemp Brachytherapy. 2021; 13(4):433-440. PMC: 8407261. DOI: 10.5114/jcb.2021.108598. View

12.

Singh A, Shields C, Shields J . Prognostic factors in uveal melanoma. Melanoma Res. 2001; 11(3):255-63. DOI: 10.1097/00008390-200106000-00007. View

13.

Kowal J, Markiewicz A, Debicka-Kumela M, Bogdali A, Romanowska-Dixon B . Outcomes of I-125 brachytherapy for uveal melanomas depending on irradiation dose applied to the tumor apex - a single institution study. J Contemp Brachytherapy. 2019; 10(6):532-541. PMC: 6335559. DOI: 10.5114/jcb.2018.79886. View

14.

. Local Recurrence Significantly Increases the Risk of Metastatic Uveal Melanoma. Ophthalmology. 2015; 123(1):86-91. DOI: 10.1016/j.ophtha.2015.09.014. View

15.

Shields C, Shields J, Cater J, Gunduz K, Miyamoto C, Micaily B . Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. Arch Ophthalmol. 2000; 118(9):1219-28. DOI: 10.1001/archopht.118.9.1219. View

16.

Sayan M, Mamidanna S, Oncel D, Jan I, Vergalasova I, Weiner J . Clinical management of uveal melanoma: a comprehensive review with a treatment algorithm. Radiat Oncol J. 2020; 38(3):162-169. PMC: 7533402. DOI: 10.3857/roj.2020.00318. View

17.

Krantz B, Dave N, Komatsubara K, Marr B, Carvajal R . Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017; 11:279-289. PMC: 5298817. DOI: 10.2147/OPTH.S89591. View

18.

Gragoudas E, Lane A, Munzenrider J, Egan K, Li W . Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma. Trans Am Ophthalmol Soc. 2003; 100:43-8; discussion 48-9. PMC: 1358945. View

19.

Melia B, Abramson D, Albert D, Boldt H, Earle J, Hanson W . Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001; 108(2):348-66. DOI: 10.1016/s0161-6420(00)00526-1. View

20.

Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V . Ocular melanoma: an overview of the current status. Int J Clin Exp Pathol. 2013; 6(7):1230-44. PMC: 3693189. View